2025-03-01 · medications, safety, glp-1, phentermine, contrave, orlistat, weight-management, adverse-events

Updated 2026-07-29

Are GLP-1 medications actually dangerous?

In pivotal trials, the dominant issues on semaglutide and tirzepatide were gastrointestinal — nausea, vomiting, constipation, and diarrhea affected 20–35% of participants and usually faded within eight weeks. Serious events (pancreatitis, gallbladder disease) were rare and mostly linked to rapid weight loss rather than direct drug toxicity. For most eligible adults the safety profile is favorable relative to untreated obesity.

What is the black-box warning on semaglutide and does it apply to me?

Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) carry a boxed warning about medullary thyroid carcinoma (MTC) based on rodent studies. The warning is absolute for anyone with a personal or family history of MTC or MEN2 syndrome. For everyone else the human evidence for a real-world signal remains unproven after 10+ years of use, and prescribing continues in that population.

Which weight-loss medication has the fewest side effects?

Orlistat (Xenical, Alli) has the mildest systemic profile because it acts in the gut and is barely absorbed, but the GI side effects — oily stools, urgency, and vitamin malabsorption — bother many users. For systemic tolerability at meaningful weight-loss doses, low-dose semaglutide often ranks best; setmelanotide is exceptionally well tolerated but is only indicated in rare genetic obesity syndromes.

Should I stop my weight-loss medication before surgery?

For GLP-1 agonists, most anesthesia societies now recommend holding weekly doses for at least one week before elective procedures under general anesthesia because delayed gastric emptying raises aspiration risk. Daily oral agents are usually held the morning of surgery. Always confirm timing with your surgical and prescribing teams — protocols shifted materially between 2023 and 2025.

Can I take a weight-loss medication if I have high blood pressure?

GLP-1 agonists and orlistat are generally fine and can modestly lower blood pressure. Phentermine and phentermine-topiramate (Qsymia) can raise heart rate and blood pressure and are avoided in uncontrolled hypertension or established cardiovascular disease. Bupropion-naltrexone (Contrave) has a smaller pressor effect but still warrants monitoring. Baseline and periodic BP checks belong in every plan.

How often should I have lab work while on weight-loss medications?

A reasonable pattern is baseline labs before starting (fasting glucose or A1c, lipid panel, LFTs, TSH, kidney function, and a pregnancy test where relevant), a 4-week clinical check-in, a 3-month efficacy check against the Endocrine Society 5%-at-3-months rule, and annual labs on chronic therapy. Qsymia adds monthly pregnancy testing for people of reproductive potential.

What red-flag symptoms mean I should stop the medication and call my doctor?

Severe persistent epigastric pain radiating to the back (possible pancreatitis), right-upper-quadrant pain with fever (gallbladder), palpitations or new chest pain on stimulant-based drugs, worsening mood or suicidal thoughts on Contrave, eye pain with vision change on topiramate, dark or bloody stools on orlistat, and severe dehydration from ongoing vomiting all warrant same-day contact and, often, holding the next dose.

Are compounded GLP-1s from med-spas safe?

The FDA lifted the semaglutide and tirzepatide shortage designations in 2024–2025, which removed the legal basis most compounding pharmacies were using. Compounded products are not FDA-approved, sterility and dosing accuracy vary widely by pharmacy, and adverse-event reports — including dosing errors from salt-form confusion — have climbed. Branded FDA-approved products remain the safer baseline whenever access allows.

Weight Loss Drug Safety

Weight-loss medications now range from a 1959-approved stimulant to triple-agonist injectables in late-phase trials, and the safety profile of each drug is genuinely different. This guide walks through what “safe” means in this context, how the major FDA-approved classes actually compare on side effects, what the black-box warnings do and do not mean, what a reasonable monitoring plan looks like, and the red-flag symptoms that need a same-day call to your clinician. The goal is to help you and your prescriber choose the option whose risks are the best fit for your medical history — not to talk anyone into or out of any specific drug.

Who this is for / not for

Good fit if:

• You are considering prescription weight-loss medications and want a safety-focused overview grounded in FDA labels and recent trials.
• You plan to review risks, interactions, and monitoring with a clinician and want to arrive prepared.
• You want to compare side-effect profiles across GLP-1s, phentermine, Contrave, Qsymia, and orlistat before choosing.

Not a fit if:

• You are trying to source medication without medical oversight — this article does not replace a prescriber.
• You are pregnant, breastfeeding, or planning pregnancy in the next two months — all currently approved weight-loss drugs are contraindicated.
• You have complex conditions (advanced kidney or liver disease, unstable psychiatric illness, active cancer) that need individualized specialist guidance rather than a general overview.

Quick stats

• GLP-1 nausea rate: roughly 40–70% of patients report some nausea during titration; severe nausea is closer to 5–10% (STEP-1, SURMOUNT-1 safety appendices).
• Phentermine cardiovascular effect: average resting heart-rate increase of about 3–5 bpm and systolic blood-pressure change of roughly ±2–5 mmHg in short-term trials.
• Orlistat GI-event rate: ~30% of users experience at least one steatorrhea, oily-stool, or fecal-urgency episode in the first year.
• Pancreatitis on GLP-1s: background rate in adults with obesity is ~1–3 per 1,000 person-years; meta-analytic signal from 38 RCTs suggests a small, statistically borderline increase attributable to the drug class (Sun 2022, BMJ).
• Gallbladder events during rapid loss: absolute risk rises by about 0.5–1.0 percentage points over placebo when weight loss exceeds ~1.5% per week on any modality.

What “safe” means for weight-loss medications

“Safe” is a comparative word, not an absolute one. For a drug to reach FDA approval for chronic weight management, it has to show meaningful weight loss (usually ≥5% placebo-adjusted at one year) and an acceptable safety margin in trials of 3,000+ people followed for at least a year. Approval does not mean zero risk; it means the benefit outweighed the risk in the studied population.

Three distinctions matter when reading safety information:

• Absolute vs. relative risk. A “50% increase” in a rare event can still be a tiny absolute change. A gallstone rate that moves from 1% to 1.5% in a year is a 50% relative increase and a 0.5-percentage-point absolute increase.
• Background rate vs. attributable rate. People with obesity already have elevated baseline rates of pancreatitis, gallstones, and cardiovascular disease. Any post-marketing signal has to be compared to what would happen without the drug in the same population.
• Boxed warnings. A boxed warning (informally, a “black box”) flags a serious concern that prescribers must acknowledge. It does not mean the event will happen — some boxed warnings are grounded in rodent-only data (see below).

Untreated obesity is not a null comparator. It carries its own well-characterized risks (cardiovascular disease, type 2 diabetes, cancer, sleep apnea, joint disease), so the honest question is not “is this drug risk-free?” but “is the drug’s risk lower than continuing untreated?”

Side-effect profiles at a glance

The table below summarizes the most-used FDA-approved options for chronic weight management. Rows are drug classes; columns cover common events (>10% incidence), serious but rare events, monitoring needs, hard contraindications, and clinician-facing notes. See the FDA-approved prescription options hub for cost, dosing, and eligibility.

Black-box and boxed warnings — what they actually mean

Three current weight-loss drugs carry boxed warnings, and each one has been misread as a much stronger prediction than the evidence supports.

• GLP-1 medullary-thyroid warning (semaglutide, tirzepatide, liraglutide). Based on rodent studies where lifetime GLP-1 exposure caused C-cell hyperplasia and MTC in rats. No confirmed human signal has emerged in more than a decade of use in millions of patients, and post-marketing surveillance has not shown an excess of MTC. That said, MEN2 and personal/family MTC history are hard exclusions because MTC arises from the same cell type the drug acts on.
• Bupropion suicidality warning (Contrave, and bupropion generally). The warning covers a small increase in suicidal thinking during antidepressant initiation, especially in adolescents and young adults. In Contrave trials specifically, rates were low and comparable to placebo, but active or recent suicidal ideation, bulimia, or anorexia are contraindications — the bupropion-plus-electrolyte-instability seizure risk is the specific concern in bulimia — and mental-health screening is expected before and during use.
• Topiramate teratogenicity in Qsymia. Topiramate in the first trimester roughly doubles the risk of oral clefts (from ~0.1% to ~0.2%). This is the reason Qsymia carries a REMS program with monthly pregnancy testing in people who can become pregnant, and it is why the drug is not started without a documented negative pregnancy test.

Read every boxed warning as “here is a specific event we want your prescriber and you to think about,” not as a prediction that the event will happen to you.

Monitoring schedule

A sensible monitoring plan is class-agnostic at the framework level and then tuned to the drug. The pattern below reflects the American Association of Clinical Endocrinology 2023 obesity algorithm and the Endocrine Society 2015 (currently under 2026 revision) guideline.

• Baseline (before first dose): vital signs, weight, waist circumference, fasting glucose or A1c, lipid panel, comprehensive metabolic panel (including LFTs and kidney function), TSH if not tested in the past year, and a pregnancy test in anyone with pregnancy potential. Confirm a full medication and supplement list to screen for interactions.
• Week 4: blood pressure and heart rate, tolerability check, hydration status, and — for GLP-1s and Qsymia — a symptom review for nausea, constipation, mood change, or tingling. Adjust titration if needed.
• Month 3 (Endocrine Society 5%-rule check): if total body weight loss is less than about 5%, discuss dose escalation, switching class, or discontinuation. This checkpoint prevents indefinite exposure to a drug that is not working for a given patient.
• Month 6 and beyond: repeat lipid panel and A1c or fasting glucose, LFTs if on Contrave or topiramate, kidney function on stimulants, and vitamin A/D/E/K on orlistat. Continue BP and HR at every follow-up.
• Annual (chronic maintenance therapy): full baseline panel repeat, weight trajectory review, and a shared decision on continuation, taper, or switch.

Rapid weight loss itself needs monitoring independent of the drug: adequate protein (roughly 1.6 g/kg body weight per day), resistance training at least twice weekly to protect lean mass (see preserving muscle during weight loss), and hydration to reduce gallstone and kidney-stone risk.

Drug interactions worth knowing

Interactions are where preventable adverse events often start. The pattern to remember is that weight-loss drugs change either absorption or the central nervous system, and both of those alter how other medications behave.

• Warfarin + orlistat. Orlistat reduces vitamin K absorption and can raise INR unpredictably. Anticoagulation clinics typically increase monitoring frequency for the first month.
• Oral contraceptives + orlistat. Diarrhea can reduce pill absorption; back-up contraception is prudent, especially in the first weeks.
• Phentermine + MAOIs. Combining a sympathomimetic with an MAOI can trigger hypertensive crisis. A 14-day washout after any MAOI is required before starting phentermine.
• GLP-1 + insulin or sulfonylurea. Adding a GLP-1 lowers glucose and raises hypoglycemia risk. Prescribers typically reduce insulin or sulfonylurea doses by 20–50% at initiation, particularly for adults with type 2 diabetes.
• Bupropion + SSRIs, tramadol, or other serotonergic agents. Increases seizure risk and can contribute to serotonin syndrome. Contrave is usually not started with a serotonergic antidepressant without a plan for cross-taper.
• Topiramate + oral contraceptives. At doses above ~200 mg per day topiramate reduces ethinyl estradiol exposure and can compromise contraceptive efficacy; Qsymia’s top dose is 92 mg/15 mg so the effect is smaller but not zero, and non-oral contraception is often recommended.
• GLP-1 + delayed-release oral drugs. Slowed gastric emptying can delay peak absorption of oral medications; separating a GLP-1 injection from time-sensitive oral drugs by a few hours helps, and switching to non-oral routes is sometimes preferred.

Red flags — when to call your clinician same-day

Most side effects are mild and self-limited. A small set are not, and the response to each of these is the same: hold the next dose and call.

• Persistent epigastric pain radiating to the back, especially with nausea or vomiting — evaluate for pancreatitis.
• Right-upper-quadrant pain with fever or jaundice — evaluate for gallstones or cholecystitis.
• Palpitations, chest pain, or resting blood pressure above ~160/100 on phentermine or Qsymia — hold and reassess.
• New or worsening mood change, hopelessness, or suicidal thoughts on Contrave or Qsymia — same-day contact and safety plan.
• Eye pain with blurred vision or halos on topiramate — evaluate for acute-angle-closure glaucoma; this can permanently damage vision within hours.
• Severe dehydration, dizziness on standing, or inability to keep fluids down on a GLP-1 — pause the drug and get IV fluids if needed. Heat exposure (sauna, hot yoga, long outdoor workouts) compounds this risk during dose titration; see the titration adjustments in our sauna and weight loss guide.
• Dark, tarry, or bloody stools on orlistat — evaluate for GI bleeding.

For a more detailed walk through the typical GLP-1 side-effect pattern, see the Ozempic side-effects guide.

Populations that need extra care

Some patient populations require a different starting posture — not necessarily a “no,” but a more careful “how.”

• Pregnancy, planned pregnancy, or breastfeeding. All currently approved weight-loss medications are contraindicated. GLP-1s require at least a 2-month washout before conception because of their long half-life. Postpartum, most agents remain contraindicated during breastfeeding.
• Adults over 65. Dose reductions and slower titration are the rule. Phentermine’s cardiovascular effects are more consequential; GLP-1-related dehydration raises fall risk; and rapid weight loss accelerates sarcopenia unless resistance training is preserved (see weight loss for older adults).
• Chronic kidney disease. Phentermine is contraindicated in moderate-to-severe CKD. GLP-1s are used with caution and adequate hydration to avoid pre-renal AKI from GI-driven dehydration. Orlistat can worsen oxalate nephropathy.
• History of pancreatitis. A relative contraindication for GLP-1s; usually managed by choosing a different class first.
• MEN2 or personal/family MTC history. Absolute contraindication for all GLP-1 agonists.
• History of eating disorders. Stimulants (phentermine, phentermine-topiramate) and appetite-suppressing agents can worsen restrictive behaviors; the eating-disorder team should be in the prescribing loop.

What the 2026 landscape looks like

Four shifts have changed the safety conversation since the last time this page was reviewed.

• Compounded-drug safety warnings have accelerated. The FDA issued repeated communications in 2024–2025 about dosing errors from salt-form confusion, sterility failures at non-503A-compliant facilities, and mismatched syringes. With the semaglutide (2025) and tirzepatide (2024) shortage designations lifted, the legal basis for most large-scale compounding is gone. For the honest picture on the current landscape see compounded semaglutide and tirzepatide.
• Oral semaglutide (Rybelsus) safety differences. The oral formulation shares the injectable’s class-effect profile but adds a food-and-water dosing ritual (empty stomach, 30 minutes before food, small water volume) that failure to follow reduces both efficacy and predictability of side effects.
• Retatrutide and other next-generation trials. Phase 3 triple-agonist data have shown larger average losses, and — so far — a side-effect profile that mirrors the GLP-1 class with somewhat higher GI intensity at maximum doses. Long-term safety data remain immature.
• Med-spa telehealth prescribing. The rise of telehealth-only prescribers of compounded GLP-1s has widened access but also increased adverse-event reports. Vetting a prescriber means confirming they hold an unrestricted license in your state, that a physician (not only a health coach) reviews your labs, and that the pharmacy dispensing is FDA-registered.
• Reported vs. attributable adverse events. The FDA’s MedWatch database captures anyone’s report of a possible side effect during drug exposure. A signal there is a hypothesis, not proof of causation. Serious post-marketing conclusions require pharmacoepidemiologic studies that adjust for the background rate of the same event in the same population — and the rebound weight gain after stopping GLP-1s is one recurring example of a real effect being amplified in patient communities before comparative data catch up.

Bottom line

Weight-loss medications are safer than they are often portrayed and less risk-free than the marketing suggests. A drug’s safety depends on the specific molecule, your history, and how the plan is monitored — pick the option whose risks are the best fit for your medical context, run a real monitoring schedule, and treat any red-flag symptom as a reason to pause and call.

Sources at a glance

• FDA prescribing labels for Wegovy, Zepbound, Saxenda, Contrave, Qsymia, phentermine, orlistat (Xenical / Alli), Imcivree, and Rybelsus — current revisions as of 2026.
• Garvey WT et al. American Association of Clinical Endocrinology 2023 clinical practice guideline on the pharmacological management of adults with obesity.
• Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1) — safety appendix. NEJM, 2021.
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — safety appendix. NEJM, 2022.
• Sun F et al. Effect of GLP-1 receptor agonists on the risk of pancreatitis: a systematic review and meta-analysis of 38 RCTs. BMJ, 2022.
• Markovic TP et al. Endocrine Society clinical practice guideline on the pharmacological management of obesity (2015; 2026 revision in review).